Document Detail

Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment.
MedLine Citation:
PMID:  20179619     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate whether the intraocular pressure (IOP) reduction and mechanism of action of timolol and latanoprost change between 1 and 6 weeks of treatment. PATIENTS AND METHODS: Thirty participants on no ocular medications completed this double-masked, 6-visit, crossover study. At each visit IOP was determined by pneumatonometry, aqueous flow by fluorophotometry, and outflow facility by fluorophotometry and tonography. Separate values of uveoscleral outflow were calculated using the Goldmann equation, an episcleral venous pressure of 11 mm Hg, and each of the 2 outflow facility values. In a randomized fashion, both eyes were treated for 6 weeks with latanoprost 0.005% once daily or timolol 0.5% twice daily. Measurements were repeated at 1 and 6 weeks of dosing. After 6 weeks of washout, the second drug was administered in a crossover manner. One and 6 weeks of treatment were compared with appropriate baselines using 1-way analyses of variance (ANOVA). RESULTS: Timolol reduced aqueous flow by 27% at week 1 (P<0.001) and 16% at week 6 (P=0.03). Latanoprost increased uveoscleral outflow several fold at each visit (P<0.05). Neither drug altered outflow facility. Neither drug showed a detectable change in aqueous humor dynamics at week 6 compared with week 1. Both drugs significantly (P<0.001) reduced IOP at 1 and 6 weeks of treatment. CONCLUSIONS: Timolol and latanoprost significantly reduce IOP by different mechanisms. Timolol reduces aqueous flow whereas latanoprost increases uveoscleral outflow. Continued treatment with timolol or latanoprost for 6 weeks did not alter effects on aqueous humor dynamics. Outflow facility changes sometimes reported with prostaglandin analogues were not detected in this study.
Thomas V Johnson; Shan Fan; Guilin Zhan; Carl B Camras; Carol B Toris
Related Documents :
21646939 - Intrathoracic pressure regulation improves 24-hour survival in a pediatric porcine mode...
15342219 - S-cone, l + m-cone, and pattern, electroretinograms in ocular hypertension and glaucoma.
2811569 - Transscleral cyclophotocoagulation using a contact laser probe: a histologic and clinic...
17509689 - Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patien...
15944999 - Central corneal thickness in primary open angle glaucoma, pseudoexfoliative glaucoma, o...
7447769 - Alternative definitions of open-angle glaucoma. effect on prevalence and associations i...
6769329 - Noninvasive assessment of load reduction in patients with asymptomatic aortic regurgita...
11380089 - Role of closed mitral commissurotomy in mitral stenosis with severe pulmonary hypertens...
12855889 - Blood loss after fluid resuscitation with isotonic or hypertonic saline for the initial...
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of glaucoma     Volume:  19     ISSN:  1536-481X     ISO Abbreviation:  J. Glaucoma     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-16     Completed Date:  2010-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9300903     Medline TA:  J Glaucoma     Country:  United States    
Other Details:
Languages:  eng     Pagination:  356-64     Citation Subset:  IM    
Department of Ophthalmology and Visual Sciences, University of Nebraska Medical Center, Omaha, NE 68198-5840, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / therapeutic use*
Aqueous Humor / drug effects,  secretion
Cross-Over Studies
Double-Blind Method
Intraocular Pressure / drug effects*
Middle Aged
Ocular Hypertension / drug therapy*,  metabolism
Prostaglandins F, Synthetic / therapeutic use*
Sclera / metabolism
Time Factors
Timolol / therapeutic use*
Tonometry, Ocular
Treatment Outcome
Uvea / metabolism
Reg. No./Substance:
0/Antihypertensive Agents; 0/Prostaglandins F, Synthetic; 130209-82-4/latanoprost; 26839-75-8/Timolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Retinal vein occlusion and angle closure: a retrospective case series.
Next Document:  Comparison of ICare rebound tonometer with noncontact tonometer in healthy children.